College Of Optometrists Launch Campaign To Raise The Public’s Awareness Around Sight Care

The College of Optometrists has announced the launch of a new eye health awareness campaign, Eyes for a Lifetime. Its communications team will undertake a series of initiatives with the national and consumer media, highlighting how eye examinations are a vital health check that should be part of everyone’s normal health regime.

The Eyes for a Lifetime campaign aims to raise awareness amongst the UK public about the importance of looking after their eyes. According to statistics, up to 2 per cent of GP visits are due to an eye complaint*. The campaign is set to help the medical profession by targeting GPs and other healthcare professionals who can help reach patients with key messages about the importance of visiting an optometrist for regular eye examinations.

The Eyes for a Lifetime campaign was launched last month with the release of new research by the College of Optometrists which revealed that one third of UK drivers are at risk of breaking the law and causing car accidents as a result of driving with poor eyesight. The research revealed that 20 per cent of drivers have taken to the roads knowing that they can’t see adequately and up to 21 per cent put off going for an eye examination for up to 5 years after noticing a deterioration in their eyesight.

The ongoing Eyes for a Lifetime campaign will focus on four themes which will be developed over the next year:

– Nutrition and eating for eye health
– Eye health in older age
– Children and looking after their eyesight
– Ethnicity and eye health

The first of these campaigns, which focuses on nutrition and commenced in March, sees the College link with nutritionist Fiona Hunter and promote the impact a healthy lifestyle and diet can have on the health of our eyes.

The subsequent campaigns will be aimed at specific target audiences, helping to raise awareness amongst ‘at risk’ groups.

Running alongside the campaigns, the College will also be producing a series of factsheets and tips on topics associated with eye health, including:

– Dry eye
– Contact lenses
– Driving and vision
– Working with VDUs

These fact sheets, and other useful information about eye health, will be available on a
brand new consumer website, to be launched in May. Eye health information can currently be found at: college-optometrists.

The College of Optometrists is the Professional, Scientific and Examining Body for Optometry in the UK and works for the public benefit. It promotes eye health and supports its Members in all aspects of professional development, enabling them to serve their patients well and contribute to the wellbeing of local communities.

* eyecasualty/maincontent1/guidetoeyeexamiantion.htm

Source
College of Optometrists

Designing a ‘bionic eye’ – Ophthalmologists and physicists team up

Stanford physicists and eye doctors have teamed up to design a “bionic eye,” of sorts. On Feb. 22 in the Journal of
Neural Engineering, Daniel Palanker, Alexander Vankov and Phil Huie from the Department of Ophthalmology and the Hansen
Experimental Physics Laboratory and Stephen Baccus from the Department of Neurobiology published a design of an
optoelectronic retinal prosthesis system that can stimulate the retina with resolution corresponding to a visual acuity of
20/80–sharp enough to orient yourself toward objects, recognize faces, read large fonts, watch TV and, perhaps most
important, lead an independent life. The researchers hope their device may someday bring artificial vision to those blind due
to retinal degeneration. They are testing their system in rats, but human trials are at least three years away.

“This is basic research,” said Palanker, a physicist whose primary appointment is in the Ophthalmology Department. “It’s the
essence of Bio-X,” he said, referring to Stanford’s interdisciplinary initiative to speed biomedical research from benchtop
to bedside.

The project is funded in part by the U.S. Air Force and VISX Corp., which licensed the technology through Stanford’s Office
of Technology Licensing. Harvey Fishman, who is not an author of the current paper but directs the Stanford Ophthalmic Tissue
Engineering Laboratory, pioneered the project.

Degenerative retinal diseases result in death of photoreceptors–rod-shaped cells at the retina’s periphery responsible for
night vision and cone-shaped cells at its center responsible for color vision. Worldwide, 1.5 million people suffer from
retinitis pigmentosa (RP), the leading cause of inherited blindness. In the Western world, age-related macular degeneration
(AMD) is the major cause of vision loss in people over age 65, and the issue is becoming more critical as the population
ages. Each year, 700,000 people are diagnosed with AMD, with 10 percent becoming legally blind, defined by 20/400 vision.
Many AMD patients retain some degree of peripheral vision.

“Currently, there is no effective treatment for most patients with AMD and RP,” the researchers say in their paper. “However,
if one could bypass the photoreceptors and directly stimulate the inner retina with visual signals, one might be able to
restore some degree of sight.”

To that end, the researchers plan to directly stimulate the layer underneath the dead photoreceptors using a system that
looks like a cousin of the high-tech visor blind engineer Lt. Geordi La Forge wore in Star Trek: The Next Generation. It
consists of a tiny video camera mounted on transparent “virtual reality” style goggles. There’s also a wallet-sized computer
processor, a solar-powered battery implanted in the iris and a light-sensing chip implanted in the retina.

The chip is the size of half a rice grain–3 millimeters–and allows users to perceive 10 degrees of visual field at a time.
It’s a flat rectangle of plastic (eventually a silicon version will be developed) with one corner snipped off to create
asymmetry so surgeons can orient it properly during implantation. One design includes an orchard of pillars: One side of each
pillar is a light-sensing pixel and the other side is a cell-stimulating electrode. Pillar density dictates image resolution,
or visual acuity. The strip of orchard across the top third of the chip is densely planted. The strip in the middle is
moderately dense, and the strip at the bottom is sparser still. Dense electrodes lead to better image resolution but may
inhibit the desirable migration of retinal cells into voids near electrodes, so the different electrode densities of a
current chip design allow the researchers to explore parameters and come up with a chip that performs optimally. Another
design–pore electrodes–involves an array of cavities with stimulating electrodes located inside each of them.

How does the system work when viewing, say, a flower? First, light from the flower enters the video camera. (Keep in mind
that camera technology is already pretty good at adjusting contrast and other types of image enhancement.) The video camera
then sends the image of the flower to the wallet-sized computer for complex processing. The processor then wirelessly sends
its image of the flower to an infrared LED-LCD screen mounted on the goggles. The transparent goggles reflect an infrared
image into the eye and onto the retinal chip. Just as a person with normal vision cannot see the infrared signal coming out
of a TV remote control, this infrared flower image is also invisible to normal photoreceptors. But for those sporting retinal
implants, the infrared flower electrically stimulates the implant’s array of photodiodes. The result? They may not have to
settle for merely smelling the roses.

Complex processing: The eyes have it

The eye is a complex machine. It has more than 100 million photoreceptors. “If we compare it to modern digital cameras, for
example, it will be 100 megapixels,” Palanker said during an interview in the Hansen Experimental Physics Laboratory. “We buy
cameras usually of three megapixels, maybe four.”

And if electronic cameras do a good job of image processing, the eye does a spectacular job, compressing information before
sending it to the brain through the 1 million axons that make up the optic nerve. “We have a built-in processor in the eye,”
Palanker said. “Before it goes into the brain, the image is significantly processed.”

The bottom layer of photoreceptors is where rhodopsin–a protein pigment that converts light into an electrical
signal–exists. But as far as signal processing is concerned, the rubber meets the road where the signal enters the inner
nuclear layer, which is populated with bipolar, amacrine and horizontal cells. These three cellular workhorses process the
signals and transfer them to the ganglion cell layer, or “output cascade” of nerves that deliver signal pulses to the brain.

It’s best to place an implant at the earliest accessible level of image processing, Palanker said. “The earliest [accessible
level] in degenerated retina is in the nuclear layer, and the more you go along the chain of image processing, the more
complex the signals become.”

The Stanford researchers try to utilize most of the processing power remaining in the retina after retinal degeneration by
placing their implant on the side of the retina facing the interior of the eye (“subretinal” placement), as opposed to
several other groups in the United States, Germany and Japan that place retinal implants on the side of the retina facing the
outside of the eyeball (“epiretinal” placement).

Signal processing allows the eye to detect direction of motion, perceive colors, enhance contrast and adjust to different
levels of brightness. “Our eye is an amazingly adjustable machine,” Palanker said. It operates in brightness levels that span
eight orders of magnitude, meaning it can detect both dim objects and those 100 million times brighter, “from moonless night
to bright day,” he said.

It may seem counterintuitive that as it gets processed by the visual system, the signal travels from the back of the eye
toward the eye’s interior, rather than from the inner surface of the retina and out the back of the eye. But metabolically
active photoreceptors need a lot of support. They are connected to a highly pigmented layer called retinal pigment epithelium
(RPE) that grows atop a highly vascularized layer of tissue (choroid) carrying a heavy flow of blood. If the blood supply and
the RPE were inside the eye, they would obscure light from the photosensitive cells. Explained Palanker: “That is why it’s
built upside down, because those cells on top–the bipolars and ganglions–do not require as many nutrients and as much
metabolic support as do photoreceptors.”

A crucial aspect of visual perception is eye motion. Palanker said the Stanford system provides a powerful advantage over
more basic devices now being tested in humans by a U.S. company because, besides making the most of the eye’s natural
image-processing strengths by subretinal placement of implants, the system tracks rapid intermittent eye movements required
for natural image perception. Vankov, a physicist, designed the projection and tracking system.

“In reality, when you think you are fixating to a certain point, your eyes are not steady,” Palanker said. “You are
microscanning it all the time. So if you would be projecting an image not through the eye, but just deliver it from the
camera to the implant, bypassing the moving eye, this will not be natural perception because you will completely eliminate
this link.”

Alon Asher, a graduate student in computer science at Tel Aviv University, spent a semester working with Palanker on the
software that links image processing to motion detection. He now continues his work on the project from Israel. Assistant
Professor of Neurobiology Stephen Baccus, a co-author of the paper who is an expert in retinal signal processing, advises the
group about the details of image processing.

In the Stanford system, image amplification and other processing occur in the hardware, outside the eye. If amplification
occurred inside the implant’s pixels, as it does in one German design, there’d be no way short of surgery to make
adjustments.

The Stanford system also makes new use of an old trick. By co-aligning real and enhanced images, it allows patients to
utilize any remaining peripheral vision while making the most of the implant. Virtual reality systems that allow co-alignment
of real and simulated views are already in use by pilots and surgeons, Palanker said. “This co-alignment of additional
information with the normal view allows surgeons to see in the microscope the operating site, while the other eye is getting
a projection of, say, a CT or MRI image of the same patient. So they can relate the information that they don’t see in the
operating site to anatomic findings and know exactly where the tumor or other problem is.”

The amazing grace of physics

The new design answers major questions about what’s feasible for bionic devices. Biology imposes limitations, such as the
needs for a system that will not heat cells by more than 1 degree Celsius and for electrochemical interfaces that aren’t
corrosive.

Current retinal implants provide very low resolution–just a few pixels. But several thousand pixels would be required for
the restoration of functional sight. The Stanford design employs a pixel density of up to 2,500 pixels per millimeter,
corresponding to a visual acuity of 20/80, which could provide functional vision for reading books and using the computer.

Physical limitations regarding electrical stimulation most likely make it impossible for implants to impart a visual acuity
of 20/10 (the sharpness required to see the bottom line on an eye chart), 20/20 (the so-called standard of good vision) or
even 20/40 (the level to which vision must be correctable to be eligible for a California driver’s license).

A major limiting factor in achieving high resolution concerns the proximity of electrodes to target cells. A pixel density of
2,500 pixels per square millimeter corresponds to a pixel size of only 20 micrometers. But for effective stimulation, the
target cell should not be more than 10 micrometers from the electrode. It is practically impossible to place thousands of
electrodes so close to cells, Palanker said. With subretinal implants but not epiretinal ones, Stanford researchers
discovered a phenomenon–retinal migration–that they now rely on to encourage retinal cells to move near electrodes–within
7 to 10 microns. Within three days, cells migrate to fill the spaces between pillars and pores.

“If the mountain doesn’t come to Muhammad, Muhammad goes to the mountain,” Palanker said. “We cannot place electrodes that
close to cells. We actually invite cells to come to the electrode site, and they do it happily and very quickly.”

Currently the researchers are testing two designs in parallel because they aren’t yet sure which will be best. One design
uses electrodes that protrude up from the chip like pillars. The pillars allow retinal cells greater access to nutrients and
let researchers affect specific cell layers by controlling the height of the pillars. But pillars expose more cells to
current, potentially heating tissue and increasing the chance for “cross-talk”–where many electrodes affect one cell. The
second design has electrodes recessed into pores, which localizes currents and makes stimulation selective, perhaps allowing
researchers to stimulate single cells.

Huie, a cell biologist and histologist, implants the chips in rats using a unique tool he and others developed. So far his
short-term rat studies show no rejection of the implants. The next step will be longer tests in rats, as well as tests in
larger animals for which models of retinal dystrophy exist. The researchers are currently shipping chips to Joseph Rizzo, a
professor of ophthalmology at Harvard Medical School, for implantation into pigs.

Professor Mark Blumenkranz, chair of the Ophthalmology Department, advises the authors about surgical issues, and Professor
Michael Marmor in that department, an expert in retinal physiology, provides advice about retinal electrophysiology. Graduate
students Ke Wang in applied physics and Neville Mehenti in chemical engineering are currently working with Fishman of the
Stanford Ophthalmic Tissue Engineering Laboratory on carbon nanotube electrodes and on chemical stimulation of the retinal
cells. Medical student Ian Chan continues to develop lithographic fabrication technology for the implants. Alex Butterwick, a
graduate student in applied physics, is studying the mechanisms of cellular damage and the safe limits of electrical
stimulation.

By Dawn Levy

COMMENT:
Daniel Palanker, Ophthalmology: (650) 725-0059, palankerstanford.edu

A photo of the researchers is available on the web at
newsphotos.stanford.edu. It is slugged “retina.”

RELEVANT WEB URLS:

DANIEL PALANKER’S WEB PAGE
stanford.edu/~palanker

News Service website:
stanford.edu/news

Stanford Report (university newspaper):
news.stanford.edu

Most recent news releases from Stanford:
stanford.edu/dept/news/html/releases.html

Contact: Dawn Levy
dawnlevystanford.edu
650-725-1944
Stanford University
stanford.edu/dept/news

Proven Stem Cell Cures Being Thwarted By Politics, Says International Advocate For The Blind

Proven cures for blindness using
adult stem cells are already available, says a noted advocate for the
blind. But these cures are being held back by politics and the use of stem
cells as a wedge issue in election campaigns, she says. Helen J. Harris,
founder and president of RP International in Los Angeles, says that even
though the main controversy revolves around ethical use of embryonic stem
cells, politics has infected the entire scientific field and has had a
chilling effect on adult stem cell applications as well.

Acrimonious political campaigns have spread misunderstanding and
discouraged funding of all stem cell research in the United States, says
Ms. Harris. For example, she points to an adult stem cell transplant
program at a Louisiana State University hospital that was quietly
discontinued in the midst of public political rancor, even though it did
not involve embryonic cells and had already led to a successful
degenerative blindness cure back in 1984, according to Ms. Harris, who had
been personally involved with the project.

Ms. Harris is herself blind, along with two of her sons, from retinitis
pigmentosa. She started RP International more than 20 years ago and has
raised million of dollars for blindness research, especially involving the
Hollywood entertainment industry. Her organization’s, annual Vision Awards
honor celebrities, scientists and other notables for outstanding
creativity. The 2006 Vision Awards in Beverly Hills took special note of
adult stem cell research by honoring a patient who was able to regain sight
thanks to the LSU technique after more than 20 years of blindness.

Dr. Gholam Peyman, the surgeon who had performed LSU’s first successful
sight-restoring surgery in New Orleans turned to Ms. Harris at the awards
and said, “Helen, had they listened to you and to me in 1984, we might have
cured not only RP but all of these diseases by now. However, since so
little was known about it, science was afraid to take the chance.”

The chilling effect has not been limited to the LSU program, Ms. Harris
says, but is a factor holding back research all around, including money
that could go to adult stem cell applications. She cites the case of
California where billions of dollars for stem cell research approved by the
voters in a 2004 ballot initiative are still being held back by two major
lawsuits against the state.

Ms. Harris announced today that her organization — which is a leader
in promoting education, research, and patient support — will establish a
new and separate, fund-raising campaign to aid development of adult stem
cell treatments for blindness and other disorders. “I’d love to discuss
with Michael J. Fox and others on all sides of this issue to find common
ground and make sure programs like that at LSU get a chance to help
millions afflicted by degenerative blindness along with other major
disorders,” says Ms. Harris.

RP International

rpinternational/index.html

ISTA Pharmaceuticals’ New Drug Application For Bepreve(TM) Accepted For Review By U.S. Food And Drug Administration

.ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced that ISTA’s New Drug Application (NDA) for Bepreve(TM) (bepotastine ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA). The Company is seeking approval for Bepreve as an eye drop treatment for ocular itching associated with allergic conjunctivitis. The Company expects a standard review of ten months and has been given a user fee action date of September 12, 2009.

ISTA’s Phase III clinical studies with Bepreve demonstrated highly statistically significant reductions in the primary endpoints of ocular itching. In addition, the results showed Bepreve had a statistically significant effect on the rapidity of response and on additional signs or symptoms of ocular allergy, including improvement in nasal symptoms. There were no serious ocular adverse events reported in patients dosed with Bepreve.

About Bepreve(TM) (bepotastine ophthalmic solution)

Assuming approval from the FDA, Bepreve would participate in ISTA’s largest market to date. IMS Health estimates the U.S. ocular allergy market generated approximately $560 million in sales in 2007. Bepreve is a non-sedating, highly selective antagonist of the histamine (H1) receptor. It has a stabilizing effect on mast cells and it suppresses the migration of eosinophils into inflamed tissues. The compound’s primary mechanisms of action are believed to make it an effective treatment against the signs and symptoms of allergic conjunctivitis.

Bepotastine was approved in Japan for use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju Pharmaceutical Co., Ltd., exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture and market bepotastine for ophthalmic use. In 2006, ISTA licensed the exclusive North American rights from Senju to an eye drop formulation of bepotastine for the treatment of allergic conjunctivitis.

About ISTA Pharmaceuticals

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA’s products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals’ website at istavision.

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by way of example, statements contained in this press release related to the FDA’s timely review and approval of Bepreve, ISTA’s belief the FDA will review and take action on Bepreve within ten months of filing and ISTA’s expectation of becoming the leading niche ophthalmic pharmaceutical company are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on ISTA’s expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others, delays and uncertainties related to the FDA or other regulatory agency approval or actions; uncertainties and risks regarding market acceptance of and demand for ISTA’s approved products; and such other risks and uncertainties as detailed from time to time in ISTA’s public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA’s Annual Report on Form 10-K for the year ended December 31, 2007, and its most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2008.

ISTA Pharmaceuticals, Inc.
istavision

View drug information on Bepreve.

Study Of Glaucoma Surgery In Medicare Patients

Ophthalmologists (Eye M.D.s) continue to develop treatments to help the more than three million Americans with glaucoma. The July issue of Ophthalmology includes a large, national study of outcomes of incisional surgeries, used to reduce pressure inside the eye, in Medicare patients. Also covered is research that may brighten the outlook for patients with end-stage glaucoma.

All types of glaucoma damage the disc of the eye’s optic nerve, compromise the transmission of images to the brain, and eventually result in blindness if untreated. Intraocular pressure (IOP) is a key measurement taken by eye specialists when screening people for glaucoma; IOP is considered elevated when it measures above 21 millimeters of mercury. In the United States, primary open-angle glaucoma (POAG) is the most common type. Many other Americans have ocular hypertension (OH), a potential precursor to glaucoma, in which fluid pressure within the eye is elevated but optic nerve damage and/or vision loss have not yet occurred. People of African or Hispanic ethnicity have a higher risk of glaucoma, and African-Americans are more likely to progress to end stage glaucoma.

Large-scale Medicare patient study evaluates glaucoma surgeries

The claims records of 14,491 Medicare beneficiaries diagnosed with glaucoma who received one of three incisional surgeries – primary trabeculectomy (PT), trabeculectomy in the presence of scarring from previous ocular surgery or trauma (TS), or implantation of a glaucoma drainage device (GDD) – between 1994 and 2003 were analyzed by Frank A. Sloan, PhD, and colleagues. “Incisional” indicates that incisions were used to accomplish the procedure. Similar procedures that use laser tools rather than incisions were not assessed in this study. Surgical treatment may be used when IOP medications become ineffective or other factors make surgery the best option. Because some studies had suggested that performing GDD earlier in complicated glaucoma cases might provide benefit with fewer adverse outcomes, Dr. Sloan’s group decided to compare GDD to PT and TS outcomes in a large, national Medicare population.

The three surgeries are designed to improve the drainage of fluid from the eye to reduce IOP. In trabeculectomy (both PT and TS), a small portion of the trabecular meshwork is removed to increase fluid flow, and in GDD a tiny implanted shunt is used to bypass the trabecular meshwork and redirect fluid flow. These incisional techniques have benefitted millions of glaucoma patients who otherwise might be blind or have very low vision. Study patients were at least 68 years of age but not older than 96 during the period analyzed. A number of important case-mix and demographic factors were controlled for by the study design. Patients’ Medicare claim records were analyzed to determine post-surgery rates of severe or less severe outcomes, the need for additional glaucoma-related surgery, or progress to low vision or blindness. Records for follow up at one, two, and when available, six years post-surgery were also analyzed.

The study found that, although adverse outcomes were uncommon for all three surgeries, rates of severe outcomes, less severe outcomes, and progression to low vision or blindness were higher for persons who received GDD than for those who received PT or TS. Also, adverse outcome rates related to trabeculectomy were somewhat higher at six-year follow up than other studies have reported. Patients treated with GDD were more likely to progress to legal blindness. Although the study population was diverse (Medicare patients who represented all areas of the U.S. and a range of ethnicities), the patients treated with GDD were disproportionately African-American, a group at higher risk than other ethnicities of developing glaucoma-related blindness.

This large study demonstrates that most of the differences in outcomes for PT, TS and GDD may be due to disease severity in the patients treated, rather than to differences in the techniques, devices, or surgeons involved in treatment, Dr. Sloan says. “As we move forward, we might expect to see a decrease in complication rates for these surgeries,” he concludes.

Hope for patients with end-stage glaucoma – with continued treatment

Doctors can honestly give their end-stage glaucoma patients hope, says a study led by Jason W. Much, M.D. The findings break new ground in an under-researched area and will help Eye M.D.s evaluate, counsel and care for patients with visual field loss due to end-stage glaucoma.”Relentless progression to (complete) blindness is not the norm in treated patients,” says Dr. Much. “Patients should be encouraged that treatment is not futile. They may retain their visual acuity for many years and be able to perform simple tasks of daily living and enjoy reading and hobbies.”

The researchers reviewed charts of 64 patients (84 eyes) with end-stage glaucoma cared for by Eye M.D.s at the University of Pennsylvania Medical Center from 1992 to 2004. All subjects were U.S. residents; most were black and had POAG. At the study baseline, the majority of patients had 20/50 visual acuity or better along with loss of most of their visual field, defined as being able to see less than a 10 degree radius from the center of the eye’s focus. Because of the decreased field of vision, these patients were all considered legally blind at the onset of the study. Fifty-six percent of eyes had had trabeculectomy and 71 percent had had laser trabeculoplasty (removal of part of the trabecular meshwork via laser). The average IOP,controlled by treatment , was 15.36 mmHg throughout the study period. At the study conclusion point, only eight in 84 eyes had 20/200 visual acuity – meaning the ability to see objects clearly and in detail was severely compromised – and in some of these eyes the loss may have resulted from progressive cataract. Few eyes suffered complete blackout of their central visual field because of glaucoma. These findings on maintenance of visual acuity were particularly encouraging in a study population that was predominantly African-American and therefore at higher risk for glaucoma progression.

About the American Academy of Ophthalmology

The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons – Eye M.D.s – with more than 27,000 members worldwide. Eye health care is provided by the three “O’s” – opticians, optometrists and ophthalmologists. It is the ophthalmologist, or Eye M.D., who can treat it all: eye diseases and injuries, and perform eye surgery. To find an Eye M.D. in your area, visit the Academy’s Web site at aao/.

Source: John Gallagher

American Academy of Ophthalmology

How An Old Drug Could Have A New Use For Treating River Blindness

Scientists at The Scripps Research Institute have discovered a potential new use for the drug closantel, currently the standard treatment for sheep and cattle infected with liver fluke. The new research suggests that the drug may be useful in combating river blindness, a tropical disease that is the world’s second leading infectious cause of blindness for humans.

The study is scheduled for publication in an advance, online Early Edition of the journal Proceedings of the National Academy of Sciences (PNAS) during the week of February 8, 2010.

The new research shows that clostanel has the potential to inhibit the molting process of the parasite that causes the disease.

“We think this finding holds terrific potential for the treatment of river blindness, one of 13 recognized neglected tropical diseases,” says Scripps Research postdoctoral fellow Christian Gloeckner, the first author of the study.

Professor Kim Janda, who is director of the Worm Institute for Research and Medicine, Ely R. Callaway Chair in Chemistry, and member of The Skaggs Institute for Chemical Biology at Scripps Research, adds that there is an urgency to fighting the infection that leads to river blindness, which is also known as onchocerciasis. Despite several eradication efforts, the disease affects more than 37 million people in Africa, Central and South America, and Yemen.

“Victims of onchocerciasis suffer severe skin lesions, musculoskeletal pain, and various stages of blindness,” says Janda, adding that patients also experience decreased body mass index, decreased work productivity, and social stigmatization.

River blindness is caused by thread-like filarial nematode worms, Onchocerca volvulus, which are transmitted among humans through the bite of a black fly. The nematodes then multiply and spread throughout the body. When they die, they cause a strong immune system response that can destroy surrounding tissue, including that of the eye. Currently, the only drug available for mass treatment of river blindness is ivermectin, and it now appears that resistance to that drug is emerging.

This creates a critical need to identify new drug targets and agents that can effectively treat the disease.

Building on Recent Discoveries

The current study builds on recent research that has implicated chitin metabolism in the larval development of the parasite O. volvulus.

Chitin is the protective outer covering that forms part of O. volvulus’s outer cuticle. While knowledge of chitin biosynthesis in nematodes is limited, scientists do know that two classes of enzymes are critical for maintenance of the pathway – chitin synthases and chitinases, digestive enzymes that break down glycosidic bonds in chitin. The dynamic synthesis and degradation of chitin by these enzymes is a prerequisite for the organism’s development and therefore a potential drug target.

Researchers in the field had recently identified and characterized one interesting chitinase from O. volvulus, OvCHT1. Although OvCHT1’s exact metabolic role is not known, it was found to be expressed only in the infective L3 larvae and to have potential involvement in host transmission, molting, and important developmental processes in the parasite. Immunoelectron microscopy analysis detected chitinase in the pharyngeal glands of O. volvulus, structures that may contain a wide variety of proteins essential for the remodeling processes during molting and the shedding of the old cuticle.

“Therefore, we focused on these enzymes,” Gloeckner says, “and reasoned that inhibiting them may eliminate onchocerciasis.”

To test these enzyme candidates, Gloeckner, Janda and their colleagues used the Johns Hopkins clinical compound library – which contains 1,514 compounds, of which 1,082 are U.S. Food and Drug Administration (FDA)-approved drugs and 432 are foreign-approved drugs – to screen for active compounds.

“We were looking for a molecule that had a dramatic effect on chitanase specific to O. volvulus,” Gloeckner explains. “The chitinase’s enzymatic activity was monitored by a fluorescent signal. A library member was scored as a “hit” when a decrease in the signal was observed. Simply stated when a huge decrease in the signal was observed, the enzyme was essentially “knocked-out.”

The screening efforts identified four known drugs namely levfloxacin, lomefloxacin, dexketoprofen, and closantel. Of these, only closantel was found to exhibit potent enough inhibition to warrant further investigation.

Cross-Country Collaboration

The next step was to find out if closantel would work in vivo, in the larvae of O. volvulus.

“The molting process is considered a potential new target for chemotherapy against onchocerciasis,” Gloeckner explains. “And since chitinases may play a key role in molting, we wanted to determine the effect of closantel on this process.” Specifically, the researchers were interested in how clostanel would disrupt molting from the L3 to L4 stage of the larvae, a critical step that occurs within the human host.

That’s when the Scripps Research team enlisted the help of Sara Lustigman’s laboratory at the Lindsley F. Kimball Research Institute at the New York Blood Center. Lustigman’s team cultured L3-stage larvae in the presence of increasing concentrations of closantel, and the number of larvae was determined on day six. The results? Closantel completely prevented molting from the L3 to L4 stage.

Gloeckner was excited by this finding. “Based on its specificity, potency, and ease of synthesis, closantel or one its analogues might represent a promising alternative or adjunct therapy in combination with ivermectin for the treatment of onchocerciasis,” he says.

Gloeckner adds that, based on this strong evidence of efficacy, he would like to take closantel into experiments with animal models.

In addition to Gloeckner, Janda, and Lustigman, authors of the article, “Repositioning of an old drug for the neglected tropical disease Onchocerciasis,” include Amanda L. Garner, Lisa Eubanks, and Gunnar Kaufmann of Scripps Research, Fana Mersha of New England Biolabs, and Yelena Oksov and Nancy Tricoche of the New York Blood Center.

This research was supported by the Worm Institute for Research and Medicine at Scripps Research.

Source:
Keith McKeown
Scripps Research Institute

Discovery Points Toward Anti-Inflammation Treatment For Blinding Disease

The discovery of an inflammatory mediator key to the blinding effects of diabetic retinopathy is pointing toward a potential new treatment, Medical College of Georgia researchers said.

Interleukin-6, known to contribute to the debilitating joint inflammation of rheumatoid arthritis, also helps ignite inflammation of the retina, a first step in a disease that is the leading cause of blindness is working-age adults, MCG researchers reported online in Investigative Ophthalmology & Visual Science.

The finding has the scientists looking at whether an interleukin-6 antibody, which is showing success in treating rheumatoid arthritis, can halt inflammation in mice with diabetic retinopathy. “We expect that this neutralizing antibody can be used to treat diabetic retinopathy in the future,” said Dr. Wenbo Zhang, assistant research scientist in MCG’s Vascular Biology Center. Drs. Zhang and Modesto Rojas, senior postdoctoral fellow, are co-first authors on the paper.

Angiotensin II, a powerful constrictor of blood vessels, is typically associated with the kidneys where it plays a vital role in regulating blood pressure. The scientists suspect angiotensin II helps promotes wound healing and regulation of pressure within small blood vessels in the eye.

However in diabetes, angiotensin II levels increase in the eye – probably in response to high glucose levels – and help promote inflammation, spurring remodeling of blood vessels and tissue destruction, Dr. Rojas said. “Vascular inflammation is one of the first steps to inducing the changes in the retina.”

MCG scientists have shown interleukin-6 is a needed accomplice whose previously undetectable levels in the eye also increase, said Dr. Ruth Caldwell, cell biologist a the Vascular Biology Center and the Charlie Norwood Veterans Affairs Medical Center and the study’s corresponding author.

With the help of interleukin-6, angiotensin II induces white blood cells to stick to the endothelial cells lining blood vessels of the retina, which slows blood flow. The white blood cells also start producing inflammatory and vascular growth factors that cause blood vessel walls to leak and thicken, further constricting blood flow. Retinal cells start dying from the reduced blood and oxygen supplies that result. In response, the body prompts growth of new blood vessels, presumably to help but instead causing more vision impairment.

If the trigger, high glucose, was temporary, these natural responses might help clear damaged cells and protect the eye. “Inflammation is a compensatory mechanism that gets activated as a survival mechanism,” Dr. Rojas said. “If it continues, the effect is bad.”

“We have known for along time if patients keep their blood sugar under perfect control, they don’t have these problems, but that’s hard,” Dr. Caldwell adds. “That is why it’s such a difficult disease.”

To examine interleukin-6’s role in the destruction, the researchers injected angiotensin II into the vitreous portion of the eyes of mice missing the gene for the inflammatory factor as well as normal mice. The extra angiotensin did little to the retinal vessels of mice lacking interleukin-6 but vessels in the normal mouse retina mimicked the inflammatory reaction found in diabetic retinopathy. When they reintroduced interleukin-6 to the genetically altered mice, the damage mimicked that of the normal mice. “So when we knock out interleukin-6, we can block the effects of angiotensin II,” Dr. Caldwell said.

The scientists want to see whether the interleukin-6 antibody can be used to prevent damage by giving it shortly after the onset of diabetes in rodents and as a treatment by using it later in the disease process.

The research was funded by the National Institutes of Health, the Department of Veterans Affairs and postdoctoral fellowship awards from the Juvenile Diabetes Research Foundation International and the American Heart Association.

Source: Toni Baker

Medical College of Georgia

New Research Reveals Unexpected Biological Pathway In Glaucoma

In a study published in the Proceedings of the National Academy of Sciences (Early Edition ahead of print), a team of researchers from the Kennedy Krieger Institute and four collaborating institutions, identified a new and unexpected biological pathway that appears to contribute to the development of glaucoma and its resulting vision loss.

Prior research has suggested that the optic nerve head, the point where the cables that carry information from the eye to the brain first exit the eye, plays a role in glaucoma. In this study, researchers report a series of findings that offer novel insights into cellular and molecular mechanisms operating at the optic nerve head in two mouse models of glaucoma. Most notably, they discovered that at a specific location within the optic nerve head, there is a unique class of cells called astrocytes that demonstrate properties that appear to make them a critical factor in the visual blinding that occurs in glaucoma.

Further, at this same site, researchers found abnormal forms of a protein called gamma synuclein that is similar to abnormal forms of alpha synuclein, a related protein known for its key role in cell loss in Parkinson’s disease. The findings suggest that a biological process similar to Parkinson’s disease unfolds in glaucoma at the specific anatomical location pinpointed in this study for the first time.

Finally, researchers discovered that at this anatomical location, there is a surprising process whereby astrocytes remove the debris of neurons, the cells that die in neurodegenerative disorders such as glaucoma. It is likely that this newly discovered process involving removal of the debris of one cell by a neighboring cell is important not only in glaucoma and Parkinson’s disease, but also for many neurodegenerative diseases.

“These findings are very exciting because they give us several novel targets for future interventions,” said Dr. Nicholas Marsh-Armstrong, senior study author and a research scientist at Kennedy Krieger Institute. “I believe these findings put us on the cusp of discovering a treatment for glaucoma that may also have relevance for a number of other neurodegenerative diseases.”

Future studies will examine this novel pathway and molecular/cellular mechanism to understand precisely what steps go awry in glaucoma and what can be controlled pharmacologically to identify interventions that slow the disease progression.

Dr. Marsh-Armstrong and other scientists at Kennedy Krieger Institute collaborated on this study with colleagues at the Johns Hopkins University School of Medicine, University of California at San Diego, Cardiff University in England, and the University of Murcia in Spain.

This research was principally supported by the Melza M. and Frank Theodore Barr Foundation through the Glaucoma Research Foundation, with additional grant funding provided in part by the International Retinal Research Foundation and the National Eye Institute of the National Institutes of Health.

About Glaucoma

Glaucoma is a neurodegenerative disorder that causes blindness by damaging the optic nerve, which sends signals from the eye to the brain. It affects more than 60 million people and is the second leading cause of blindness worldwide. While older individuals are at higher risk for the disease, babies and children are also susceptible to glaucoma, especially those with certain neurological disorders.

Source: Kennedy Krieger Institute

Significance of VEGF164 in Pathological Neovascularization (underlying cause of eye diseases)

Eyetech Pharmaceuticals, Inc announced today that research in vascular endothelial growth factor (VEGF) suggest that
specific isoforms may play important roles in neovascular disease in the human eye. Results from a study in mice provide
evidence that the presence of a specific isoform called VEGF164 is not required to drive normal vascular development in the
retina. However, by specifically targeting this isoform, there is a reduction in abnormal blood vessel growth (pathological
angiogenesis) which results in diseases of the retina. These data were presented today at the 2005 Association for Research
in Vision and Ophthalmology annual meeting in Fort Lauderdale, Fla.

VEGF and its role in the cause and progression of certain eye diseases such as neovascular age-related macular degeneration
(neovascular AMD) have become increasingly important. VEGF is a protein that is responsible for stimulating abnormal blood
vessel growth and blood vessel leakage in diseases such as neovascular AMD, diabetic retinopathy and retinal vein occlusion.

“This study provides further evidence that by specifically targeting the pathologic or ‘bad’ isoform, we can block
undesirable blood vessel growth while still permitting the ‘good’ blood vessel growth and maintenance required for healthy
and normal function of the eye,” said Anthony P. Adamis, M.D., Chief Scientific Officer of Eyetech. “Therefore, selective
inhibition of pathological forms of VEGF may provide a more optimal balance of safety and efficacy in treating an underlying
cause of neovascular AMD.”

The study, a collaboration among researchers at Eyetech Pharmaceuticals and Schepens Eye Institute at Harvard Medical School,
was designed to characterize the role of different VEGF isoforms in inflammation and pathological neovascularization. The
study utilized three models — retinopathy of prematurity (ROP), laser-induced choroidal neovascularization (CNV) and
delayed-type hypersensitivity (DTH) — to examine the pro-inflammatory and angiogenic outcomes in a population of study mice
who were VEGF164-deficient, but still harbored two other VEGF isoforms VEGF120 and VEGF188. VEGF164 is the mouse equivalent
of isoform VEGF165 in humans. The data presented are based on observations reported from animal studies. The clinical
significance in humans is unknown.

Results of the ROP model, which was used to quantify the physiological and pathological neovascularization in the eye,
suggest that there were no developmental differences between wild-type mice and those deficient in the VEGF164 isoform.
However, the ROP model showed that pathological neovascularization in the study mice was reduced by 90 percent compared to
wild-type mice, an outcome which the authors attribute to the significant decrease in retinal inflammatory cells, which are
known to drive the abnormal angiogenesis in ROP. Results in the CNV model showed that laser-induced CNV lesions in the eyes
of the study mice were 44 percent smaller than in the wild-type mice. Data from these two models indicate that VEGF164 is not
required for normal development of the retina, but instead specifically induces inflammation and pathological
neovascularization, and is more potent in doing so than the other VEGF isoforms. Data from the DTH model, which was used to
measure inflammation and characterize the role of VEGF164 outside of the eye, confirmed that the absence of VEGF164 resulted
in a significant decrease in inflammatory response, characterized by leukocyte accumulation and tissue edema in the ear skin
of mice. This response showed that the pro-inflammatory nature of VEGF164 is not isolated to ocular tissues.

Anti-VEGF therapy appears to target an underlying cause of all neovascular AMD and may have potential benefits in a wide
range of therapeutic areas. Macugen(R) (pegaptanib sodium injection) is a pegylated anti-VEGF aptamer, which binds to the
specific isoform VEGF165, which is believed to be an underlying cause for the pathological blood vessel growth and leakage in
ocular neovascularization in humans. Macugen interrupts the VEGF cascade and the associated neovascularization by selectively
blocking VEGF and the science strongly suggests that this selectivity is the reason why no physical destruction of
vasculature has been observed in connection with use of Macugen.

About Macugen

Macugen is indicated in the United States for the treatment of neovascular age-related macular degeneration and is
administered in a 0.3 mg dose once every six weeks by intravitreal injection. For full prescribing information about Macugen,
please visit macugen.

Important safety information

Macugen is contraindicated in patients with ocular or periocular infections.

Intravitreal injections including those with Macugen have been associated with endophthalmitis. Proper aseptic injection
technique — which includes use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent) — should
always be utilized when administering Macugen. In addition, patients should be monitored during the week following the
injection to permit early treatment, should an infection occur.

Increases in intraocular pressure (IOP) have been seen within 30 minutes of injection with Macugen. Therefore, IOP as well as
the perfusion of the optic nerve head should be monitored and managed appropriately.

Serious adverse events related to the injection procedure occurring in

Making Smart Phone Touch-Screens More Glare And Smudge Resistant

Scientists have discovered the secret to easing one of the great frustrations of the millions who use smart phones, portable media players and other devices with touch-screens: Reducing their tendency to smudge and cutting glare from sunlight. In a report at the 238th National Meeting of the American Chemical Society, they describe development of a test for performance of such smudge- and reflection-resistant coatings and its use to determine how to improve that performance.

Steven R. Carlo, Ph.D., and colleagues note in the new study that consumer electronics companies value the appearance of their flagship devices just as much as their functionality. As a result, smudge, scratch and reflective resistant coatings have become standard on high-end touch-screen cell phones and MP3 players. These coatings are effective. However, their structure and mechanisms are poorly understood, so Carlo and colleagues developed a test to determine the chemical composition and effectiveness of smudge and reflective resistant materials. The test could also lead to a better understanding of the chemistry of these coatings and allow improved formulations and performance, Carlo says.

“Surfaces are particularly important in consumer products. This work investigates how products can be modified to reduce smudging and reflections. These modifications can offer improved resistance to fingerprints, anti-reflection properties or enhanced physical resistance,” Carlo explains.

The basis of anti-smudge coatings is a compound called perfluoro alkyl ether, a derivative of Teflon with added ether groups to enhance its repellent effects. Anti-reflective materials use alternating layers of material, including silica and aluminum layers, to bend and diffuse light to reduce glare.

Since traditional chemical techniques could not be used on these super-thin coatings, Carlo and his team used depth profile X-ray photoelectron spectroscopy (XPS). That’s a tool for comparing the chemistry of these coatings to predict their performance. The data allowed them to compare chain length, degree of branching and the hydrocarbon and fluoroether content of various samples. The fluoroether content has a key effect in enhancing efficacy. Anti-reflective coatings need alternating layers, which have differences in their refractive index (RI), a measure of how fast light travels through a material. Fluorocarbons in general have low RI and they offer anti-smudge properties. XPS allowed the scientists to visualize the multi-layer structure and the chemical species present in each layer. In general, the greater the number of layers there are in a coating, the greater the anti-reflective properties. Carlo and his team also discovered that more silica and aluminum layers led to better glare reduction.

Source:
Michael Bernstein

American Chemical Society